Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SRZN
- Price
- 9.45
- Stock movement up
- +0.10 (1.07%)
- Company name
- Surrozen Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 30.71M
- Ent value
- 42.03M
- Price/Sales
- 2.17
- Price/Book
- 5.42
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -15.85%
- 3 year return
- -42.71%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-10
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SRZN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.17 |
| Price to Book | 5.42 |
| EV to Sales | 2.97 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.25M |
| EPS (TTM) | -13.77 |
| FCF per share (TTM) | -8.36 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 14.15M |
| Gross profit (TTM) | 9.22M |
| Operating income (TTM) | -26.63M |
| Net income (TTM) | -44.44M |
| EPS (TTM) | -13.77 |
| EPS (1y forward) | -8.11 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 65.19% |
| Operating margin (TTM) | -188.26% |
| Profit margin (TTM) | -314.14% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 31.01M |
| Net receivables | 12.20M |
| Total current assets | 45.29M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 48.00M |
| Accounts payable | 276.00K |
| Short/Current long term debt | 1.53M |
| Total current liabilities | 6.12M |
| Total liabilities | 42.33M |
| Shareholder's equity | 5.67M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -28.42M |
| Capital expenditures (TTM) | 7.00K |
| Free cash flow (TTM) | -26.99M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -784.15% |
| Return on Assets | -92.58% |
| Return on Invested Capital | -617.71% |
| Cash Return on Invested Capital | -375.20% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 9.98 |
| Daily high | 10.22 |
| Daily low | 8.84 |
| Daily Volume | 10K |
| All-time high | 180.45 |
| 1y analyst estimate | 33.00 |
| Beta | 0.94 |
| EPS (TTM) | -13.77 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| SRZN | S&P500 | |
| Current price drop from All-time high | -94.76% | -10.49% |
| Highest price drop | -97.25% | -56.47% |
| Date of highest drop | 9 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -83.04% | -11.07% |
| Avg time to new high | 154 days | 12 days |
| Max time to new high | 895 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
30.71M
Marketcap category
Small-cap
Description
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Employees
42
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partner